標(biāo)題: Titlebook: Cellular Therapies for Retinal Disease; A Strategic Approach Steven D. Schwartz,Aaron Nagiel,Robert Lanza Book 2017 Springer International [打印本頁(yè)] 作者: 調(diào)停 時(shí)間: 2025-3-21 17:49
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease影響因子(影響力)
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease被引頻次
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease被引頻次學(xué)科排名
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease年度引用
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease年度引用學(xué)科排名
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease讀者反饋
書(shū)目名稱(chēng)Cellular Therapies for Retinal Disease讀者反饋學(xué)科排名
作者: 尖叫 時(shí)間: 2025-3-22 00:19
Scope of services to be outsourced, RPE monolayer and facilitate manipulation and subretinal implantation. An ideal scaffold should mimic the properties of the natural RPE substrate: Bruch’s membrane. It should have a similar thickness, flexibility, micro- and macromolecule permeability, and the ability to promote survival, polarity,作者: Synovial-Fluid 時(shí)間: 2025-3-22 03:32 作者: hurricane 時(shí)間: 2025-3-22 04:43 作者: 跳脫衣舞的人 時(shí)間: 2025-3-22 11:28 作者: 波動(dòng) 時(shí)間: 2025-3-22 13:11
Book 2017t of surgically delivered cellular therapies. Having an in-depth understanding ofthe current state of cell therapy for the eye is an essential first step toward utilizing similar approaches in other organs. Ophthalmologists, translational clinician-scientists, stem cell scientists, and researchers i作者: 波動(dòng) 時(shí)間: 2025-3-22 19:14 作者: 飛鏢 時(shí)間: 2025-3-22 21:27 作者: Pericarditis 時(shí)間: 2025-3-23 04:55
Subretinal Delivery of Cells via the Suprachoroidal Space: Janssen Trialtes to the subretinal space. After considering a number of potential techniques, they developed a novel approach using the suprachoroidal space as a conduit to the posterior pole. This approach involves the creation of a sclerotomy, introduction of a specialized cannula into the suprachoroidal space作者: 紅潤(rùn) 時(shí)間: 2025-3-23 07:48
Retinal Organoids: An Emerging Technology for Retinal Disease Research and Therapyoes not reproduce that of late fetal development. However, studies to date suggest that immature photoreceptor or retinal ganglion cells, roughly those of mid-gestation, function best for transplantation. This developmental stage appears to be well reproduced in vitro, and therefore the PSC-derived 作者: 細(xì)絲 時(shí)間: 2025-3-23 10:25
nt state of cell therapy for the eye is an essential first step toward utilizing similar approaches in other organs. Ophthalmologists, translational clinician-scientists, stem cell scientists, and researchers i978-3-319-84169-4978-3-319-49479-1作者: innovation 時(shí)間: 2025-3-23 17:41 作者: bronchiole 時(shí)間: 2025-3-23 19:35 作者: Rejuvenate 時(shí)間: 2025-3-24 01:04
Book 2017ect the choriocapillaris, retinal pigment epithelium, photoreceptors, and retinal ganglion cells. Instead of utilizing a disease-centric approach to the topic, this book—edited by two world-renowned stem cell scientists—focuses on strategies for developing and transplanting the cells. This includes 作者: nullify 時(shí)間: 2025-3-24 04:46 作者: incubus 時(shí)間: 2025-3-24 08:28 作者: Iniquitous 時(shí)間: 2025-3-24 14:12
Outsourcing to India - A Legal Handbook We further discuss the translational progress of cell transplantation for different cell types and the prospects of harnessing the endogenous regenerative potential of the eye. This discussion provides insights to achieve the goal of restoring vision in glaucoma using cell therapy.作者: negligence 時(shí)間: 2025-3-24 16:09
Outsourcing to India - A Legal Handbooke 1 clinical trials using intravitreal autologous bone marrow CD34+ or mononuclear cells show no safety or feasibility issues associated with the cell therapy. Larger studies are needed to determine the full?safety profile and therapeutic potential of these cells.作者: 微生物 時(shí)間: 2025-3-24 20:02 作者: Curmudgeon 時(shí)間: 2025-3-25 01:15 作者: backdrop 時(shí)間: 2025-3-25 06:45
Induced Pluripotent Stem Cell-Derived Autologous Cell Therapy for Age-Related Macular Degenerationtrates morphological, molecular, and functional attributes that are similar to the native tissue. We have confirmed safety and efficacy of this tissue . in an RPE injury pig model. Our results provide a potential treatment for AMD using autologous iPS cells.作者: 審問(wèn) 時(shí)間: 2025-3-25 08:33 作者: RAFF 時(shí)間: 2025-3-25 15:26
Autologous Bone Marrow-Derived Cell Therapies for Retinal Diseasee 1 clinical trials using intravitreal autologous bone marrow CD34+ or mononuclear cells show no safety or feasibility issues associated with the cell therapy. Larger studies are needed to determine the full?safety profile and therapeutic potential of these cells.作者: 注意到 時(shí)間: 2025-3-25 19:07
“Disease in a Dish” Modeling of Retinal Diseasesf opportunity in the search for treatment of retinal disease, including testing for efficacy of gene or drug-based therapies, elucidating previously unknown mechanisms and pathways of disease, and using iPSCs as a source of autologous cells for cell replacement therapy.作者: 在前面 時(shí)間: 2025-3-25 23:21
stem cell therapies for ophthalmologic diseases.Focuses on This book familiarizes the reader with the current landscape of cell-based therapies for the treatment of retinal disease, including diseases that affect the choriocapillaris, retinal pigment epithelium, photoreceptors, and retinal ganglion作者: 支柱 時(shí)間: 2025-3-26 01:29
https://doi.org/10.1007/978-3-540-72153-6PE) cell transplantation therapy for retinal regeneration. The MA09-(hESC) line was derived from the blastomere stage of a donated embryo and expanded on mitotically inactivated mouse embryonic fibroblasts according to the Good Manufacturing Practices. The MA09-hRPE cells were then tested for safety作者: GIST 時(shí)間: 2025-3-26 07:35 作者: 拱墻 時(shí)間: 2025-3-26 09:28
Outsourcing to India - A Legal HandbookPE). Replacement of the atrophied RPE cell layer has previously shown potential to preserve visual acuity in autograft surgeries. However, these procedures are risky and complicated. RPE cells derived from patient-specific induced pluripotent stem (iPS) cells can be reproducibly manufactured as a ti作者: oblique 時(shí)間: 2025-3-26 16:02
Scope of services to be outsourced,retinal pigmented epithelium (RPE) resulting in photoreceptor loss. Replacement of lost RPE cells with stem cell-derived RPE (SC-RPE) in patients with AMD and similar retinal diseases is currently being tested in clinical trials. Subretinal delivery of cell suspensions of SC-RPE is being investigate作者: 剛毅 時(shí)間: 2025-3-26 20:04 作者: 興奮過(guò)度 時(shí)間: 2025-3-26 21:14
Outsourcing to India - A Legal Handbookdegeneration of optic nerve. Like other parts of the central nervous system, retinal ganglion cells do not regenerate. Current therapies may prevent or delay further damage, but cannot restore vision. Cell transplantation therapies hold great promise for slowing disease progression and restoring vis作者: 我說(shuō)不重要 時(shí)間: 2025-3-27 03:13
Outsourcing to India - A Legal Handbook. The rationale for exploring this therapy is that there is preclinical evidence showing that certain stem cells in bone marrow can have a regenerative effect on ischemic or degenerating retina. Direct tissue incorporation and paracrine trophic effects of bone marrow stem cells have been demonstrate作者: 整頓 時(shí)間: 2025-3-27 06:46 作者: burnish 時(shí)間: 2025-3-27 10:51 作者: AXIOM 時(shí)間: 2025-3-27 16:26 作者: elastic 時(shí)間: 2025-3-27 19:18 作者: CORE 時(shí)間: 2025-3-27 21:59
http://image.papertrans.cn/c/image/223073.jpg作者: Asymptomatic 時(shí)間: 2025-3-28 03:02
https://doi.org/10.1007/978-3-319-49479-1Cell-based Neuroprotection; Cell Transplantation; Choriocapillaris; Pluripotent Stem Cells; Retinal Pigm作者: 白楊 時(shí)間: 2025-3-28 06:20
978-3-319-84169-4Springer International Publishing AG 2017作者: AWE 時(shí)間: 2025-3-28 10:33
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cell Transplantation for Retinal DegenePE) cell transplantation therapy for retinal regeneration. The MA09-(hESC) line was derived from the blastomere stage of a donated embryo and expanded on mitotically inactivated mouse embryonic fibroblasts according to the Good Manufacturing Practices. The MA09-hRPE cells were then tested for safety作者: handle 時(shí)間: 2025-3-28 17:58
Stem Cell-Derived RPE Transplantation: The Feasibility and Advantages of Delivery as Monolayersl-retina and choroid and provides physiological . to the overlying retina. Conditions and diseases that affect the RPE have a serious impact on normal retinal structure and function and thus on sight. The most prevalent among them, age-related macular degeneration is the leading cause of blindness i作者: 不要不誠(chéng)實(shí) 時(shí)間: 2025-3-28 22:24
Induced Pluripotent Stem Cell-Derived Autologous Cell Therapy for Age-Related Macular DegenerationPE). Replacement of the atrophied RPE cell layer has previously shown potential to preserve visual acuity in autograft surgeries. However, these procedures are risky and complicated. RPE cells derived from patient-specific induced pluripotent stem (iPS) cells can be reproducibly manufactured as a ti作者: 不在灌木叢中 時(shí)間: 2025-3-29 01:42
Scaffolds for Cell Transplantationretinal pigmented epithelium (RPE) resulting in photoreceptor loss. Replacement of lost RPE cells with stem cell-derived RPE (SC-RPE) in patients with AMD and similar retinal diseases is currently being tested in clinical trials. Subretinal delivery of cell suspensions of SC-RPE is being investigate作者: 會(huì)議 時(shí)間: 2025-3-29 05:20 作者: Ophthalmoscope 時(shí)間: 2025-3-29 07:56
Cell Transplantation Therapy for Glaucomadegeneration of optic nerve. Like other parts of the central nervous system, retinal ganglion cells do not regenerate. Current therapies may prevent or delay further damage, but cannot restore vision. Cell transplantation therapies hold great promise for slowing disease progression and restoring vis作者: voluble 時(shí)間: 2025-3-29 12:04 作者: COW 時(shí)間: 2025-3-29 18:50
Subretinal Delivery of Cells via the Suprachoroidal Space: Janssen Trialtinal space, which has traditionally been accomplished through conventional pars plana vitrectomy with the creation of a retinotomy and subsequent transfer of cells. Delivering cells in this fashion is thought to incur a risk of retinal detachment and the development of proliferative vitreoretinopat作者: 干涉 時(shí)間: 2025-3-29 21:05 作者: ANTH 時(shí)間: 2025-3-30 00:17 作者: misshapen 時(shí)間: 2025-3-30 06:29
